Prevention of iatrogenic transmission of B19 infection: Different approaches to detect, remove or inactivate virus contamination

Clinical Laboratory

Volumn 52, Issue 5-6, 2006, Pages 263-268

  Bonvicini, Francesca ^a   Gallinella, Giorgio ^a   Gentilomi, Giovanna Angela ^a   Ambretti, Simone ^a   Musiani, Monica ^a   Zerbini, Marialuisa ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Heat treatments; Nanofiltration; NAT tests; Parvovirus B19; Plasma products; Solvent detergent treatments

Indexed keywords

LIPID;

BLOOD; ERYTHEMA INFECTIOSUM; HEAT SENSITIVITY; IATROGENIC DISEASE; INFECTION PREVENTION; NANOFILTRATION; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PARVOVIRUS; PASTEURIZATION; QUANTITATIVE ANALYSIS; REVIEW; SAFETY; SENSITIVITY AND SPECIFICITY; VIRAL CONTAMINATION; VIRUS CAPSID; VIRUS DETECTION; VIRUS ENVELOPE; VIRUS INACTIVATION; VIRUS TRANSMISSION; BLOOD COMPONENT THERAPY; CLASSIFICATION; DISEASE TRANSMISSION; DISINFECTION; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; STANDARD; VIRUS INFECTION;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; MIRIDAE; PARVOVIRUS;

BLOOD COMPONENT TRANSFUSION; DISINFECTION; HUMANS; IATROGENIC DISEASE; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN;

EID: 33745877932     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Manaresi E, Gallinella G, Morselli Labate AM. Seroprevalence of IgG against conformational and linear capsid antigens of parvovirus B19 in Italian blood donors. Epidemiol Infect 2004; 132: 857-62
2. Zerbini M, Musiani M. Human Parvoviruses. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds). Manual of Clinical Microbiology, 2003; 8th edn: 1534-43
3. Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 1999; 13: 194-204
4. Cohen BJ, Beard S, Knowles WA et al. Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion. Transfusion 1997; 37(9):947-52
5. Human Anti-D immunoglobulin. In: European Pharmacopoeia monograph. Document 01:557
6. Saldanha J, Lelie N, Yu MW, Heath A, the B19 Collaborative Study Group. Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques. Vox Sang 2002; 82: 24-31
7. Voluntary recall of pooled plasma, solvent-detergent treated. In: FDA, Center for Biologics Evaluation and Research. 1999
8. Bonvicini F, Gallinella G, Cricca M et al. Molecular testing for detection of in vitro infectivity of plasma pools contaminated with B19 virus. J Med Virol 2004; 74: 272-6
9. Gallinella G, Moretti E, Nardi G. Analysis of B19 virus contamination in plasma pools for manufacturing, by using a competitive polymerase chain reaction assay. Vox Sang 2002; 83: 324-331
10. Koppelman HGM, Cuypers T, Emrich T, Zaaijer H. Quantitative real-time detection of parvovirus B19 DNA in plasma. Transfusion 2004; 44: 97-103
11. Gallinella G, Zerbini M, Musiani M, Venturoli S, Gentilomi GA, Manaresi E. Quantitation of parvovirus B19 DNA sequences by competitive PCR: differential hybridization of the amplicons and immunoenzymatic detection on microplate. Mol Cell Probes 1997; 11: 127-33
12. Sato K, Matsuda E, Kamisango K, Iwasaki H, Matsubara S, Matsunaga Y. Development of a hypersensitive detection method for human parvovirus B19 DNA. J Clin Microbiol 2000; 38: 1241-3
13. Daly P, Corcoran A, Mahon BP, Doyle S. High-sensitivity PCR detection of parvovirus B19 in plasma. J Clin Microbiol 2002; 40: 1958-62
14. Manaresi E, Gallinella G, Zuffi E, Bonvicini F, Zernini M, Musiani M. Diagnosis and quantitative evaluation of parvovirus B19 infections by real-time PCR in the clinical laboratory. J Med Virol 2002; 67: 275-81
15. Harder TC, Hufnagel M, Zahn K et al. New LightCycler PCR for rapid and sensitive quantification of parvovirus B19 DNA guides therapeutic decision-making in relapsing infections. J Clin Microbiol 2001; 39: 4413-9
16. Aberham C, Pendl C, Gross P, Zerlauth G, Gessner M. A quantitative, internally controlled real-time PCR assay for the detection of parvovirus B19 DNA. J Virol Methods 2001;92: 183-91
17. Gallinella G, Venturoli S, Manaresi E, Musiani M, Zerbini M. B19 virus genome diversity: epidemiological and clinical correlations. J Clin Virol 2003; 28: 1-13
18. Nguyen QT, Sifer C, Schneider V, Bernaudin F, Auguste V, Garbarg-Chenon A. Detection of an erythrovirus sequence distinct from B19 in a child with acute anaemia. Lancet 1998; 352: 1524
19. Nguyen QT, Sifer C, Schneider V et al. Novel human erythovirus associated with transient aplastic anemia. J Clin Microbiol 1999; 37: 2483-7
20. Hokynar K, Norja P, Laitinen H et al. Detection and differentiation of human parvovirus variants by commercial quantitative real-time PCR tests. J Clin Microbiol 2004; 42: 2013-9
21. Baylis SA, Shah N, Minor PD. Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma. J Virol Methods 2004; 121: 7-16
22. Schmidt I, Blumel J, Seitz H, Willkommen H, Lower J. Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sang 2001; 81: 228-35
23. Prowse C, Ludlam CA, Yap PL. Human parvovirus B19 and blood products. Vox Sang 1997; 72: 1-10
24. Laurian Y, Dussaix E, Parquet A, Chalvon-Demersay A, d'Oiron R, Tchernia G. Transmission of human parvovirus B19 by plasma derived factor VIII concentrates. Nouv Rev Fr Hematol 1994; 36: 449-53
25. Solheim BG, Rollag H, Svennevig JL, Arafa O, Fosse E, Bergerud U. Viral safety of solvent/detergent-treated plasma. Transfusion 2000; 40: 84-90
26. Koenigbauer UF, Eastlund T, Day JW. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion 2000; 40: 1203-6
27. Brause W, Mertens H, Kalus M, Lefevre H. Quantification of antibodies against parvovirus B19 and hepatitis A in SD-plasma. Vox Sang 1998; 74: 1120
28. Just B, Lefevre H. Detection of parvovirus B19 DNA in solvent-detergent plasma. Vox Sang 2002; 83: 167
29. Saldanha J, Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 1996; 93: 714-9
30. Blumel J, Schmidt I, Willkommen H, Lower J. Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 2002; 42: 1011-8
31. Yunoki M, Urayama T, Tsujikawa M et al. Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulins preparations. BJR 2004; 128: 401-4
32. Yunoki M, Tsujikawa M, Urayama T et al. Heat sensitivity of human parvovirus B19. Vox Sang 2003; 84: 164-9
33. Prikhod'ko GG, Vasilyeva I, Reyes H et al. Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies. Transfusion 2005; 45: 1011-9
34. Abe H, Sugawara H, Hirayama J et al. Removal of parvovirus B19 from hemoglobin solution by nanofiltration. Artif Cells Blood Substit Immobil Biotechnol 2000; 28: 375-83
35. Yokoyama T, Murai K, Murozumo T et al. Removal of small non-enveloped viruses by nanofiltration. Vox Sang 2004; 86: 225-9